Karen B. Miller

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein et al. · Journal of Clinical Oncology · 2020 · 242 citations

Medicine, Oncology, Pharmacology +17

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Johanna C. Bendell, Philippe L. Bédard, Yung‐Jue Bang et al. · Cancer Research · 2020 · 64 citations

Life Sciences, Immunology, Oncology +17

NMDA Receptor Blockade and Spinal Cord Ischemia Due to Aortic Crossclamping in the Rat Model

Fabrizio Follis, Karen B. Miller, Oscar U. Scremin et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 1994 · 35 citations · Full text

Medicine, Neuroscience, Pharmacology +14

Isotype-specific plasma cells express divergent transcriptional programs

Brett W. Higgins, Andrew G. Shuparski, Karen B. Miller et al. · Proceedings of the National Academy of Sciences · 2022 · 32 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Degeneration of axons in the corticospinal tract secondary to spinal cord ischemia in rats

Karen S. Blisard, Fabrizio Follis, R. Wong et al. · Spinal Cord · 1995 · 20 citations

Medicine, Neurobiology, Neuroscience +14